【드래곤 스포츠】 보증업체놀이터추천홍보 : 프로그램제작판매제작의뢰 : 스포츠분석 : 무료스포츠중계tv : 섹시bj움짤 : 뉴스 : 안구정화

로그인

글쓰기

[IT뉴스]Celltrion Adds $70 Million to Share Buybacks as Earnings Rise

온카뱅크관리자

2026-10-26 13:37:26

<div class="article_view" data-translation-body="true" data-tiara-layer="article_body" data-tiara-action-name="본문이미지확대_클릭"> 
 <section dmcf-sid="z5Gw7yJ6rc">
 [NA Eun-kyung, Edaily Reporter] Celltrion said Monday it will buy back an additional 100 billion won ($70 million) of its own shares, bringing the total value of share repurchases authorized this year to 500 billion won ($350 million).
 The company said its board approved the purchase of 514,404 shares through open-market transactions between Oct. 27 and Jan. 26, 2027.
 The decision marks Celltrion's fifth share buyback authorization this year. The company approved repurchases worth 100 billion won each in April, May, August and September. Including the latest authorization, the company has announced plans to acquire 2.65 million shares worth a combined 500 billion won.
 Celltrion has pursued share repurchases since 2022 as part of its efforts to support its stock price and return capital to shareholders. It bought back approximately 886 billion won in shares in 2023 and 534.6 billion won in 2024. The company continued its buyback and cancellation programs in 2025.
 The drugmaker has also stepped up share cancellations, which permanently reduce the number of shares outstanding. It canceled approximately 1.8 trillion won in treasury shares in April and announced another cancellation worth about 100 billion won in September.
 However, Celltrion has not decided whether to cancel the shares covered by its latest buyback authorization.
 The company said it will seek shareholder feedback at its annual general meeting in March 2027 before deciding whether to cancel additional treasury shares or increase cash dividends. The decision will take into account its full-year financial results, distributable profits and market conditions.
 Under a shareholder return policy introduced in August, Celltrion aims to distribute approximately one-third of its annual consolidated net profit through share cancellations, cash dividends or other measures.
 The latest buyback comes as Celltrion reports stronger earnings, supported by growing global sales of its biosimilar medicines.
 The company recently projected third-quarter revenue of 1.5 trillion won and operating profit of 510 billion won. It attributed the improvement to increased prescriptions of its products in overseas markets and a growing contribution from newer, higher-margin medicines.
 Celltrion said it intends to balance shareholder returns with continued investment in research and development and manufacturing capacity.
 "We will continue investing in the company's growth while consistently implementing our long-term principle of returning one-third of consolidated net profit to shareholders," a company spokesperson said.
 <figure class="figure_frm origin_fig" contents-hash="ef1e5069bc040746e54e6348f5bacac07ef047007a3c6eebe00d78a52aa6f49d" dmcf-pid="Qzpv4FcnIR" dmcf-ptype="figure">
 <img alt="Celltrion Adds $70 Million to Share Buybacks as Earnings Rise" class="thumb_g_article" data-org-src="https://t1.daumcdn.net/news/202610/26/Edaily/20261026133326002nyqp.jpg" data-org-width="800" dmcf-mid="7M5ObHoMOk" dmcf-mtype="image" height="auto" src="https://img1.daumcdn.net/thumb/R658x0.q70/?fname=https://t1.daumcdn.net/news/202610/26/Edaily/20261026133326002nyqp.jpg" width="658">
 <figcaption class="txt_caption default_figure">
 Celltrion Adds $70 Million to Share Buybacks as Earnings Rise
 </figcaption>
 </figure>
 나은경 (eeee@edaily.co.kr) 
 </section> 
 </div> 
 Copyright © 이데일리. 무단전재 및 재배포 금지.

댓글 총 0개

이번주 포인트랭킹

매주 일요일 밤 0시에 랭킹을 초기화합니다.

14,000상품권
23,000상품권
32,000상품권

업체홍보/구인 더보기

지식/노하우 더보기

판매의뢰 더보기

포토 더보기